Keywords: r-pr, licenses, novartis, revasc, rhone-poulenc, rorer, licensed

R-PR Licenses Novartis' Revasc

Article | 30 June 1998

Rhone-Poulenc Rorer has licensed global rights to Novartis' newrecombinant thrombin inhibitor Revasc (desirudin), in a move designed to broaden R-PR's ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

heparin

Enoxaparin Sodium Injection

Lovenox

Go to drug listing